Literature DB >> 15326486

Interleukin 24 is induced by the RET/PTC3 oncoprotein and is an autocrine growth factor for epithelial cells.

Shogo Shinohara1, Jay L Rothstein.   

Abstract

Thyroid cancers, like hematological malignancies, are commonly associated with chromosomal translocations leading to the formation of fusion proteins. Through altered signaling by fusion proteins, cell death and survival pathways are disrupted and the physiological balance of cell-cell communication may be lost. A consequence of this disruption is the release of factors by stressed cells that alert the host. One type of host response is leukocytic infiltration that may develop into chronic inflammation or autoimmune disease. Although inflammation can be associated with neoplastic tissue, the mechanism driving this process is largely unknown. Therefore, to address the mechanism of cancer inflammation we investigated the effects of an oncogene in a murine model system. A comprehensive genetic analysis revealed several soluble factors that were induced by RET/papillary thyroid carcinoma (PTC)3 gene expression including several proinflammatory cytokines, chemokines and immunologically relevant costimulatory molecules. Following a large genetic screen using RP3-expressing thyroid cells, we identified a highly abundant transcript and later identified it as interleukin 24 (Il24), a cytokine with diverse tumor suppressor and inflammatory activities. We show that RET/PTC3 induces Il24 expression in rat thyrocytes and that this expression is dependent on the signaling properties of its tyrosine kinase. Likewise, RET/PTC3 induces large amounts of Il24 following expression in murine thyrocytes, but its expression is dramatically reduced in poorly differentiated carcinomas, a finding that parallels the loss of RET/PTC3 expression. Consistent with its behavior as a tumor suppressor, the loss of Il24 coincided with the loss of RET/PTC3 in poorly differentiated mouse tumors. A functional role of Il24 in the autocrine growth/survival of RET/PTC3-expressing thyroid cells was identified helping to support its role in cellular transformation. These data suggest that the induction of Il24 by oncogenes may support tumor growth at the early stages of cancer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15326486     DOI: 10.1038/sj.onc.1207964

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  12 in total

Review 1.  The immune network in thyroid cancer.

Authors:  Maria Rosaria Galdiero; Gilda Varricchi; Gianni Marone
Journal:  Oncoimmunology       Date:  2016-03-30       Impact factor: 8.110

2.  Is diffuse and peritumoral lymphocyte infiltration in papillary thyroid cancer a marker of good prognosis?

Authors:  D G P N Villagelin; R B Santos; J H Romaldini
Journal:  J Endocrinol Invest       Date:  2011-07-13       Impact factor: 4.256

3.  Interleukins as markers of inflammation in malignant and benign thyroid disease.

Authors:  Xeni Provatopoulou; Despoina Georgiadou; Theodoros N Sergentanis; Eleni Kalogera; John Spyridakis; Antonia Gounaris; George N Zografos
Journal:  Inflamm Res       Date:  2014-05-03       Impact factor: 4.575

4.  Identification of functionally distinct TRAF proinflammatory and phosphatidylinositol 3-kinase/mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (PI3K/MEK) transforming activities emanating from RET/PTC fusion oncoprotein.

Authors:  Josephine H F Wixted; Jay L Rothstein; Laurence C Eisenlohr
Journal:  J Biol Chem       Date:  2011-12-09       Impact factor: 5.157

5.  Inflammation in thyroid oncogenesis.

Authors:  Federica Liotti; Carla Visciano; Rosa Marina Melillo
Journal:  Am J Cancer Res       Date:  2012-04-21       Impact factor: 6.166

Review 6.  Thyroid Autoimmunity and Thyroid Cancer: Review Focused on Cytological Studies.

Authors:  Francesco Boi; Fabiana Pani; Stefano Mariotti
Journal:  Eur Thyroid J       Date:  2017-04-24

7.  AZD1480 blocks growth and tumorigenesis of RET- activated thyroid cancer cell lines.

Authors:  Joana P Couto; Ana Almeida; Laura Daly; Manuel Sobrinho-Simões; Jacqueline F Bromberg; Paula Soares
Journal:  PLoS One       Date:  2012-10-02       Impact factor: 3.240

8.  Clinical and pathological implications of concurrent autoimmune thyroid disorders and papillary thyroid cancer.

Authors:  L L Cunha; R C Ferreira; M A Marcello; J Vassallo; L S Ward
Journal:  J Thyroid Res       Date:  2011-02-17

9.  How to Treat a Signal? Current Basis for RET-Genotype-Oriented Choice of Kinase Inhibitors for the Treatment of Medullary Thyroid Cancer.

Authors:  Hugo Prazeres; Joana Torres; Fernando Rodrigues; Joana P Couto; João Vinagre; Manuel Sobrinho-Simões; Paula Soares
Journal:  J Thyroid Res       Date:  2011-06-23

Review 10.  mda-7/IL-24: multifunctional cancer-specific apoptosis-inducing cytokine.

Authors:  Pankaj Gupta; Zao-zhong Su; Irina V Lebedeva; Devanand Sarkar; Moira Sauane; Luni Emdad; Michael A Bachelor; Steven Grant; David T Curiel; Paul Dent; Paul B Fisher
Journal:  Pharmacol Ther       Date:  2006-02-07       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.